User login
Key clinical point: Hepatocellular carcinoma patients who achieved complete remission with postoperative treatment after reduction hepatectomy fared better than those who achieved remission without postoperative treatment.
Major finding: The 5-year overall survival rate and mean survival time after reduction hepatectomy were 15.7% and 28.40 months for the entire study population. The 5-year overall survival and mean survival times were 37.5% and 56.55 months, respectively, for patients who achieved complete remission with postoperative treatment, compared to 6.3% and 14.84 months, respectively, for those who achieved complete remission without postoperative treatment (P = 0.0041).
Study details: The data come from a review of 30 adults with advanced hepatocellular carcinoma who underwent reduction hepatectomy at a single center between 2000 and 2018.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Asahi Y et al. World J Gastrointest Surg. 2021 Oct 27. doi: 10.4240/wjgs.v13.i10.1245.
Key clinical point: Hepatocellular carcinoma patients who achieved complete remission with postoperative treatment after reduction hepatectomy fared better than those who achieved remission without postoperative treatment.
Major finding: The 5-year overall survival rate and mean survival time after reduction hepatectomy were 15.7% and 28.40 months for the entire study population. The 5-year overall survival and mean survival times were 37.5% and 56.55 months, respectively, for patients who achieved complete remission with postoperative treatment, compared to 6.3% and 14.84 months, respectively, for those who achieved complete remission without postoperative treatment (P = 0.0041).
Study details: The data come from a review of 30 adults with advanced hepatocellular carcinoma who underwent reduction hepatectomy at a single center between 2000 and 2018.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Asahi Y et al. World J Gastrointest Surg. 2021 Oct 27. doi: 10.4240/wjgs.v13.i10.1245.
Key clinical point: Hepatocellular carcinoma patients who achieved complete remission with postoperative treatment after reduction hepatectomy fared better than those who achieved remission without postoperative treatment.
Major finding: The 5-year overall survival rate and mean survival time after reduction hepatectomy were 15.7% and 28.40 months for the entire study population. The 5-year overall survival and mean survival times were 37.5% and 56.55 months, respectively, for patients who achieved complete remission with postoperative treatment, compared to 6.3% and 14.84 months, respectively, for those who achieved complete remission without postoperative treatment (P = 0.0041).
Study details: The data come from a review of 30 adults with advanced hepatocellular carcinoma who underwent reduction hepatectomy at a single center between 2000 and 2018.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Asahi Y et al. World J Gastrointest Surg. 2021 Oct 27. doi: 10.4240/wjgs.v13.i10.1245.